COGT Cogent Biosciences, Inc.
$32.01▲ +3.56%
Healthcare
Other
Volume 1.84M
Avg Volume (10D) 2.32M
Key Metrics & Fundamentals
Market Cap
$5.55B
P/E Ratio
–
Div Yield
0.00%
52W Range
13.78 - 43.73
% vs 50 MA
-2.15%
% vs 200 MA
-10.51%
RSI-14
54.6
MACD Histogram
+0.4000
Beta (1Y vs SPY)
2.50
Free Cash Flow
-$77.64M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$93.82M
COGS
–
Operating Exp
$102.64M
Operating Income
-$102.64M
EBIT
-$102.64M
Pretax Income
-$96.41M
Net Income
-$96.41M
EPS (Diluted)
-0.52
Price & Volume History
Loading chart…
Recent News
Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
GlobeNewswire · Oct 27, 2026 4:01 PM ET
Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?
Insider Monkey · Oct 20, 2026 12:32 PM ET
Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
Simply Wall St. · Sep 25, 2026 6:10 AM ET
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
Simply Wall St. · Sep 24, 2026 2:12 PM ET
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
Simply Wall St. · Sep 24, 2026 8:11 AM ET
Cogent Biosciences Gets US FDA Acceptance for Bezuclastinib AdvSM Application
MT Newswires · Sep 15, 2026 9:20 AM ET
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
GlobeNewswire · Sep 15, 2026 8:00 AM ET
Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia
MT Newswires · Sep 2, 2026 5:33 PM ET
Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing
MT Newswires · Aug 31, 2026 5:08 PM ET
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks · Aug 13, 2026 9:55 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See COGT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.